Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma

Abstract

Although DC therapy appears safe and resulted in an immunological response in patients with refractory sarcoma, it resulted in an improvement of the clinical outcome in only a small number of patients. Cancer 2017;123:1576-1584. © 2017 American Cancer Society.

Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+conventional dendritic cells

“…21 22 Mifamurtide, a liposome-encapsulated immunotherapy that activates pulmonary macrophages, improved the disease-free and overall survival of patients with osteosarcoma lung metastases. 23 By contrast, MoDC vaccines have yielded little to no clinical responsiveness, [24][25][26] while checkpoint blockade with PD-1 or CTLA-4 antibodies led to objective clinical response rates of approximately 5% in osteosarcoma patients. 27 28 These results underscore the critical need to improve therapeutic options for osteosarcoma.…”

Immunotherapy for osteosarcoma: Where do we go from here?

“…DC vaccines have produced delays in disease progression and even the regression of established osteosarcomas in animal models . However, only limited activity was seen in the two clinical trials using DC vaccines pulsed with autologous tumor cell lysate in patients with recurrent osteosarcoma . These studies did, however, show that this strategy is safe and can activate the immune system to some extent.…”

Potential of immunotherapy for sarcoma

“…The clinical efficacy of DC‐based immunotherapy demonstrated by Miwa et al was modest. Future clinical studies of immunotherapy augmented by bacterial therapy may provide much better outcomes, and it should be evaluated in clinical trials in the near future.…”

“…OK‐432 is a preparation from Streptococcus pyogenes that has been reported to be immunomodulatory . In the study by Miwa et al, increased levels of serum interferon‐γ and interleukin 12 were seen after DC‐based immunotherapy, and this indicated that DC‐based immunotherapy activated the immune responses of the patients. No adverse effects associated with the DC‐based immunotherapy were observed in the study patients.…”

“…In the current issue of Cancer , Miwa et al evaluate the efficacy of autologous tumor lysate–pulsed DC therapy in a phase 1/2 trial of refractory bone and soft tissue sarcomas. They prepared DCs from blood monocyte precursors from the study patients.…”